Veeva Systems (NYSE: VEEV) is scheduled to report first-quarter fiscal 2027 results after market close today, with a stock that is under pressure on the year. The cloud software provider has been building a little momentum in recent weeks, with the Veeva stock price up 3.76% on the month, yet the past year has been a difficult one of underperformance for holders, with VEEV down 38% since this time last year.
Expectations are for growth, with the street looking for an EPS of $2.14, representing 8.4% growth from the year-ago result of $1.97. Revenue consensus sits at approximately $857.73 million, for a 13% annual growth rate.
The Q1 FY2027 print will give fresh insight into Veeva’s cloud platform adoption across its life sciences customer base, particularly around two key product families: Vault CRM and Quality Cloud.
Recent customer wins suggest momentum may be building. Teva Pharmaceuticals committed to expanding its use of Vault CRM globally in late May, citing the platform’s technical foundation for commercial execution. Separately, Kindeva, a global contract development and manufacturing organisation, adopted the full Veeva Quality Cloud suite, including QualityDocs, QMS, Training, and LearnGxP, to standardise quality management across its manufacturing sites.
These announcements came just days before the earnings date, so the financial impact won’t appear in Q1 results. Still, management commentary on the deals and the broader pipeline will matter for investors assessing the company’s ability to expand wallet share with existing customers and land new accounts.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Subscription services revenue remains the largest component of Veeva’s business, and this will be the main line item to monitor. Growth in this segment signals sustained demand for the company’s cloud products, while any deceleration could raise questions about competitive pressure or slower life sciences IT spending.
Analyst consensus for the quarter stands at:
- Earnings per share: $2.14 (range $2.10 to $2.19)
- Revenue: $857.73 million (range $854.5 million to $874.42 million)
- Year-ago EPS: $1.97
The tight range on both EPS and revenue estimates suggests the analyst community has converged around similar assumptions for the quarter. With 26 analysts covering the stock, the level of sell-side attention is solid for a mid-cap software name.
What To Watch
Guidance adjustments
If management raises full-year revenue or EPS guidance, shares are likely to respond positively. Conversely, any downward revision, even if Q1 beats, could weigh on the stock. Veeva’s guidance track record and the company’s visibility into its subscription backlog mean investors pay close attention to forward commentary.
Subscription revenue growth
A material acceleration or deceleration in subscription services growth will influence sentiment. Strong growth would suggest the company is successfully upselling existing customers and winning new logos, while weaker growth could raise concerns about market saturation or competitive dynamics.
Operating margin performance
Veeva has historically maintained healthy margins. Any sign of margin compression, whether from increased sales and marketing spend, product development costs, or pricing pressure could trigger concern. On the other hand, margin expansion would reinforce the scalability of the business model.
Customer win commentary
While the Teva and Kindeva deals were announced before the print, investors will listen for management’s broader assessment of the sales pipeline, deal velocity, and the mix of new customers versus expansions. Life sciences IT budgets can be lumpy, so colour on customer spending behaviour will matter.
Competitive positioning
Veeva operates in a relatively concentrated market, but competitors in adjacent categories including broader enterprise software providers continue to evolve their offerings. Any commentary on competitive win rates or product differentiation could influence investor confidence.
